Four Prenylflavone Derivatives with Antiplasmodial Activities from the Stem of Tephrosia purpurea subsp. leptostachya.[Pubmed: 28891957]

None

Determination of flavonoids, polyphenols and antioxidant activity of Tephrosia purpurea: a seasonal study.[Pubmed: 27854196]

None

Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.[Pubmed: 27372406]

Tephrosia purpurea (T. purpurea) has been reported to prevent cataract formation in senile cataract model as well as proven effective in STZ induced type 1 diabetes. Aldose reductase (AR) is a key enzyme in the intracellular polyol pathway responsible for the development of diabetic cataract.

Effect of flavonoid rich fraction of Tephrosiapurpurea (Linn.) Pers. on complications associated with streptozotocin-induced type I diabetes mellitus.[Pubmed: 29466624]

Globally, diabetes is a serious health issue affecting one in 11 adults and consumes 12% of global health expenditure. Prevalence of dyslipidemia in diabetes is not uncommon since decades. Further, patients with type II diabetes have 2-4 folds more risk for cardiovascular disease (CVD). Plants with antioxidant potential are known to have beneficial effects in diabetes and its complications: Natural compounds, flavonoids particularly, ameliorate hyperglycemia as well as CVD. Here, we evaluated common wasteland weed Tephrosia purpurea, used traditionally as folk medicine to treat many disorders including diabetes. We studied the effect of 8-wk treatment of flavonoid-rich fraction of T. purpurea (FFTp) (40 mg/kg/day/p.o.) on various biochemical, cardiovascular and lenticular parameters on streptozotocin (STZ) (45 mg/kg, i.v.) induced type I diabetic rats. STZ administration produced significant hyperglycemia, dyslipidemia, and altered cardiac biomarkers like lactate dehydrogenase, creatinine kinase and reduced antioxidants in lenticular tissues of rats. Treatment with FFTp significantly prevented STZ-induced hyperglycemia, dyslipidemia as well as cardiovascular markers. We observed decreased rate of pressure development (+dp/dt) and decay (-dp/dt) in STZ diabetic hearts which was prevented by FFTp. Further, the soluble protein levels and the antioxidants were also elevated in the diabetic rats by the treatment. In conclusion, our data suggest that FFTp produces beneficial effects on diabetes induced cardiovascular complications and cataract. Such beneficial actions may be attributed to the antioxidant property of flavonoids, quercetin or rutin, present in T. purpurea.

Phylogenetic Diversity and Antifungal Activity of Endophytic Fungi Associated with Tephrosia purpurea.[Pubmed: 26839503]

Sixty-one endophytic fungus strains with different colony morphologies were isolated from the leaves, stems and roots of Tephrosia purpurea with colonization rates of 66.95%, 37.50%, and 26.92%, respectively. Based on internal transcribed spacer sequence analysis, 61 isolates were classified into 16 genera belonging to 3 classes under the phylum Ascomycota. Of the 61 isolates, 6 (9.84%) exhibited antifungal activity against one or more indicator plant pathogenic fungi according to the dual culture test. Isolate TPL25 had the broadest antifungal spectrum of activity, and isolate TPL35 was active against 5 plant pathogenic fungi. Furthermore, culture filtrates of TPL25 and TPL35 exhibited greater than 80% growth inhibition against Sclerotinia sclerotiorum. We conclude that the endophytic fungal strains TPL25 and TPL35 are promising sources of bioactive compounds.

Effect of Aqueous Extract of Tephrosia purpurea on Cardiovascular Complications and Cataract Associated with Streptozotocin-induced Diabetes in Rats.[Pubmed: 26798165]

Tephrosia purpurea has been reported to possess antidiabetic activity, however, its effects on cardiovascular complications and cataract associated with diabetes have not been studied. The objective of the present study was to investigate the effects of aqueous extract of Tephrosia purpurea on cardiovascular complications and cataract associated with streptozotocin-induced diabetes in rats. Sprague Dawley rats of either sex were made diabetic with streptozotocin (45 mg/kg, i.v.). Treatment of aqueous extract of Tephrosia purpurea was given in the dose of 300 and 500 mg/kg/day, p.o for 8 weeks. Various hemodynamic (blood pressure, heart rate, +dp/dt, -dp/dt) and biochemical (serum glucose, cholesterol, triglycerides, creatinine, urea, lactate dehydrogenase and creatinine kinase) parameters were recorded after 8 weeks of the treatment. To evaluate cataract, various biochemical estimations were done in eye lens. Streptozotocin produced hyperglycemia; hypoinsulinemia; hyperlipidemia; increased blood pressure; increased creatinine, cardiac enzymes, reduction in heart rate and cardiac hypertrophy in rats and all these changes were prevented by the treatment with aqueous extract of Tephrosia purpurea in both the doses. Streptozotocin also produced decrease in soluble protein and reduced glutathione in lens of rats that was prevented by aqueous extract of Tephrosia purpurea. Our data suggest that aqueous extract of Tephrosia purpurea prevents not only the streptozotocin-induced metabolic abnormalities but also cardiovascular complications as well as reduce the risk of development of cataract.

A novel benzofuran, 4-methoxybenzofuran-5-carboxamide, from Tephrosia purpurea suppressed histamine H1 receptor gene expression through a protein kinase C-δ-dependent signaling pathway.[Pubmed: 26619301]

Histamine H1 receptor (H1R) gene is upregulated in patients with allergic rhinitis (AR), and its expression level is strongly correlated with the severity of allergic symptoms. We previously reported isolation of the putative anti-allergic compound, 4-methoxybenzofuran-5-carboxamide (MBCA) from Tephrosia purpurea and its chemical synthesis (Shill et al., Bioorg Med Chem 2015;23:6869-6874). However, the mechanism underlying its anti-allergic activity remains to be elucidated. Here, we report the mechanism of MBCA on phorbol 12-myristate-13-acetate (PMA)- or histamine-induced upregulation of H1R gene expression in HeLa cells, and in vivo effects of MBCA were also determined in toluene-2,4-diisocyanate (TDI)-sensitized rats. MBCA suppressed PMA- and histamine-induced upregulation of H1R expression at both mRNA and protein levels and inhibited PMA-induced phosphorylation of PKCδ at Tyr(311) and subsequent translocation to the Golgi. Furthermore, MBCA ameliorated allergic symptoms and suppressed the elevation of H1R and helper T cell type 2 (Th2) cytokine mRNAs in TDI-sensitized rats. Data suggest that MBCA alleviates nasal symptoms in TDI-sensitized rats through the inhibition of H1R and Th2 cytokine gene expression. The mechanism of its H1R gene suppression underlies the inhibition of PKCδ activation.